Barely Significant

Excerpts

514,629 sentences

marginally significantp = 0.0070.1× alphagold
Importantly, similar to the behavioral results, pairwise comparisons showed no difference between sequence and random trials in block 1 ( p = 0.53) and block 2 ( p = 0.94) but did show higher levels of caudate activation for sequence versus random trials in block 3 ( p = 0.040; marginally significant after Bonferroni correction for the four comparisons) and block 4 ( p = 0.007; full significance after Bonferroni correction).
The neural basis of implicit perceptual sequence learning.
Front Hum Neurosci · 2011 · PMC3213531
nearly significantp = 0.0070.1× alphagold
To evaluate whether any SCL-90-R questionnaire scales were associated with HippAM 5-HT 2A receptor BI (mean = 266.82, sd = 114.09), the partial correlation analysis (controlled for age: mean = 45.74, sd = 9.78) including all MRD patients showed a nearly significant positive correlation with the SCL-90-R subscale HOS only [(mean = 11.42, sd = 4.30), r (16) = 0.64, p = 0.007].
an increasing trendp = 0.0070.1× alphagold
Results Among 587,049 patients with CRD, all‐cause mortality had an increasing trend during the post‐initial COVID‐19 pandemic period (incidence rate ratio (95% CI): 1.019 (1.005, 1.034); p = 0.007), compared with pre‐COVID‐19 pandemic period.
borderline significancep=0.0070.1× alpha
Further multivariate analysis found that DM (hazard ratio [HR], 2.68; 95% CI, 1.10 to 6.54; p=0.051 [borderline significance]) ( Fig. 1A ), age (HR, 2.82; 95% CI, 1.47 to 5.40; p=0.007), histology (HR, 6.61; 95% CI, 2.44 to 17.94; p=0.006), and DSI (HR, 2.53; 95% CI, 1.32 to 4.87; p=0.007) were independent adverse prognostic factors for RFS ( Table 4 ).
nominally significantP =0.0070.1× alphagold
When the rs1800532 variant was selected for attempted suicides, the heterogeneity decreased slightly (from 62.5–60.7%) and the pooled ORs showed a nominally significant harmful trend for the minor allele (1.22 (1.05–1.41), P =0.007, power of 99%) ( Figure 5 ).
showed a trendp = 0.0070.1× alpha
In a planned interim report of the FOxTROT phase III trial presented at ASCO 2020, investigating the efficacy and safety of neoadjuvant chemotherapy in 1053 T3-4, N0-2 colon cancer patients, relapse or persistent disease after two years showed a trend toward improvement at 15.6% for neoadjuvant chemotherapy vs. 19.5% for adjuvant chemotherapy ( p = 0.007) [ 43 ].